SUVENPHAR2020-01-012020-03-31in-bse-fin:OneOperatingExpenses01Member SUVENPHAR2020-01-012020-03-31in-bse-fin:OneOperatingExpenses02Member SUVENPHAR2020-01-012020-03-31in-bse-fin:FourOperatingExpenses01Member SUVENPHAR2020-01-012020-03-31in-bse-fin:FourOperatingExpenses02Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares SUVENPHAR 2019-04-01 2020-03-31 2020-06-15 INR Lakhs Yearly Single segment Contract Development and Manufacturing Operations (CDMO) 2020-01-01 2020-03-31 Audited Standalone 1847645000.00 53400000.00 1901045000.00 642421000.00 0.00 -112724000.00 195218000.00 72037000.00 70534000.00 349162000.00 1216648000.00 684397000.00 0.00 684397000.00 134907000.00 17083000.00 151990000.00 0.00 532407000.00 0.00 0.00 0.00 0.00 532407000.00 -1385000.00 531022000.00 0.00 0.00 127282000.00 1 4.18 4.18 0.00 0.00 4.18 4.18 1) The above results were reviewed by the Audit Committee of the Board and approved by the Board of Directors' at their meeting held on 18th June,2020. n2) This is the first financial results of the Company published in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the quarter and year ended 31st March,2020 following listing of 127,282,478 fully paid equity shares of Re. 1 each of the Company on BSE Limited (BSE) and National Stock Exchange of India (NSE) in March 2020. The aforesaid shares were allotted at par in terms of the Composite Scheme of Arrangement ('the Scheme') on 27th January, 2020 for an aggregated sum of Rs. 1,272.82 Lakhs, earlier credited to equity share suspense and since then transferred to equity share capital. n3)** Consequent to the demerger of Contract Research and Manufacturing services (CRAMS) Undertaking of the erstwhile Suven Life Sciences Limited as a going concern into the Company, pursuant to the Scheme effective from appointed date being 1st October,2018, the financial results for the year ended 31st March,2020 are not comparable to that extent with the previous corresponding period. Further, for the purpose of calculating earnings per share for the year ended 31st March,2019, the equity shares issued pursuant to the Scheme have been considered effective as on 1st October,2018 and the equity shares of the Company outstanding stand cancelled from the aforesaid date. n4) The Suven Life Sciences Limited (SLSL/Demerged Company) has to transfer the statutory and regulatory licenses with in India and Outside India so as to enable the Company (SPL) to carry on the business in its name. The process of obtaining the approvals from all departments is a lengthy process. In order to maintain the continuity of the business during these statutory approvals period,SLSL is continuing the CRAMS business in its own name on behalf of SPL. However, for all such operations which were recorded in the books of SPL, the same may be continued till the migration of all licenses in the name of SPL. n5) The Company's reportable activity falls under single business segment and hence,the segment disclosure requirements are not applicable. n6)** The figures for the year ended 31st March, 2019 represents figures from 01st October, 2018 (Appointed date of demerger of Demerged Undertaking into the Company) to 31st March, 2019. n7) The figures for the quarters ended 31st March, 2020 and 31st March, 2019 are the balancing figures between audited figures in respect of the full financial years and the published unaudited year to date figures upto third quarter of the respective financial years. Also, the figures upto the end of the third quarter were only reviewed and not subjected to audit. Single segment 2019-04-01 2020-03-31 Audited Standalone 8337897000.00 181173000.00 8519070000.00 2402435000.00 0.00 -110544000.00 737223000.00 218126000.00 238601000.00 1457326000.00 4943167000.00 3575903000.00 0.00 3575903000.00 888094000.00 -12993000.00 875101000.00 0.00 2700802000.00 0.00 0.00 0.00 0.00 2700802000.00 -8180000.00 2692622000.00 0.00 0.00 127282000.00 1 7701016000.00 21.22 21.22 0.00 0.00 21.22 21.22 Manufacturing Expenses 264352000.00 Other Expenses 84810000.00 Manufacturing Expenses 1057514000.00 Other Expenses 399812000.00